Steven Albelda

US Patent:

8476420, Jul 2, 2013

Filed:

Dec 5, 2008

Appl. No.:

12/745991

Inventors:

Michael Showe - Media PA, US
Louise Showe - Media PA, US
Malik Yousef - Dabburiya Village, IL
Steven M. Albelda - Bala Cynwyd PA, US
Anil Vachani - Merion Station PA, US
Andrei V. Kossenkov - Huntingdon Valley PA, US

Assignee:

The Wistar Institute of Anatomy and Biology - Philadelphia PA
The Trustees of the University of Pennsylvania - Philadelphia PA

International Classification:

C12N 15/11
C12N 15/113
C12N 15/12
C07H 21/04
C12Q 1/68

US Classification:

536 243, 536 231, 536 232, 536 235, 435 614

Abstract:

Methods and compositions are provided for diagnosing lung cancer in a mammalian subject by use of three or more selected genes, e. g. , a gene expression profile, from the peripheral blood mononuclear cells (PBMC) of the subject which is characteristic of disease, a stage of the disease, or enables prognosis of recurrence of disease. The gene expression profile includes three or more genes of Table I, Table II, Table III, Table IV, Table V, Table VI or Table VII herein. Detection of changes in expression in the selected genes forming the gene expression profile from that of a reference gene expression profile are correlated with non-small cell lung cancer (NSCLC). One composition for use in such diagnosis includes three or more PCR primer-probe sets, wherein each primer-probe set amplifies a different polynucleotide sequence from the gene expression profile. Another composition for similar use contains a plurality of polynucleotides immobilized on a substrate, which probes hybridize to three or more gene expression products from genes in the gene expression profile. Still another composition involves detection of the protein expression products of genes from the gene expression profile.

US Patent:

20030206911, Nov 6, 2003

Filed:

May 28, 2003

Appl. No.:

10/446422

Inventors:

Vladimir Muzykantov - Warwick PA, US
Steven Albelda - Bala Cynwyd PA, US

International Classification:

A61K039/395
C07K016/46

US Classification:

424/181100, 530/391100

Abstract:

A method for enhancing intracellular delivery of effector molecules is provided. The method involves modifying selected antibodies with biotin and streptavidin, conjugating these antibodies with an effector molecule, and delivering the conjugated effector to an intracellular target specifically recognized by the antibody.

US Patent:

20050226850, Oct 13, 2005

Filed:

Jun 8, 2005

Appl. No.:

11/148575

Inventors:

Susanne Brown - Glasgow, GB
Alasdair MacLean - Glasgow, GB
Nigel Fraser - Philadelphia PA, US
Bruce Randazzo - Philadelphia PA, US
Steven Albelda - Philadelphia PA, US
Larry Kaiser - Philadelphia PA, US
John Kucharczuk - Philadelphia PA, US

International Classification:

A61K048/00

US Classification:

424093200

Abstract:

A mutant herpes simplex virus which has been modified in the γ34.5 gene such that the gene is non-functional is used to treat a non-neuronal cancer such as a mesothelioma, ovarian carcinoma, bladder cancer or melanoma. Typically, the mutant herpes simplex virus has been modified within the BamHI restriction fragment of the long terminal repeat of the viral genome.

US Patent:

20070264644, Nov 15, 2007

Filed:

Nov 16, 2006

Appl. No.:

11/560410

Inventors:

Louise Showe - Media PA, US
Anil Vachani - Merion Station PA, US
Steven Albelda - Bala Cynwyd PA, US

International Classification:

C12Q 1/68

US Classification:

435006000

Abstract:

The present invention is a method distinguishing between head and neck squamous cell carcinoma and lung squamous cell carcinoma. In particular, a 10-gene classifier has been identified which can be used to distinguish between primary squamous cell carcinoma of the lung and metastatic head and neck squamous cell carcinoma. These genes include CXCL13, COL6A2, SFTPB, KRT14, TSPYL5, TMP3, KLK10, MMP1, GAS1, and MYH2. A panel of one or more of these genes, or proteins encoded thereby, can be used for early diagnosis and selection of an appropriate therapeutic treatment.

US Patent:

20070292394, Dec 20, 2007

Filed:

Jun 19, 2007

Appl. No.:

11/765189

Inventors:

Susanne Brown - Glasgow, GB
Alasdair Maclean - Glasgow, GB
Nigel Fraser - Philadelphia PA, US
Bruce Randazzo - Philadelphia PA, US
Steven Albelda - Philadelphia PA, US
Larry Kaiser - Philadelphia PA, US
John Kucharczuk - Philadelphia PA, US

International Classification:

A61K 48/00
A61P 35/04

US Classification:

424093200

Abstract:

A mutant herpes simplex virus which has been modified in the γ34.5 gene such that the gene is non-functional is used to treat a non-neuronal cancer such as a mesothelioma, ovarian carcinoma, bladder cancer or melanoma. Typically, the mutant herpes simplex virus has been modified within the BamHI restriction fragment of the long terminal repeat of the viral genome.

US Patent:

20110195053, Aug 11, 2011

Filed:

Apr 20, 2011

Appl. No.:

13/090983

Inventors:

Susanne M. Brown - Glasgow, GB
Alasdair R. Maclean - Glasgow, GB
Nigel W. Fraser - Philadelphia PA, US
Bruce P. Randazzo - Philadelphia PA, US
Steven Albelda - Philadelphia PA, US
Larry Kaiser - Philadelphia PA, US
John Kucharczuk - Philadelphia PA, US

Assignee:

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA - Philadelphia PA
CRUSADE LABORATORIES LIMITED - Aldwych
WISTAR INSTITUTE - Philadelphia PA

International Classification:

A61K 35/76
A61P 35/00
A61P 35/04

US Classification:

424 936

Abstract:

A mutant herpes simplex virus which has been modified in the γ34.5 gene such that the gene is non-functional is used to treat a non-neuronal cancer such as a mesothelioma, ovarian carcinoma, bladder cancer or melanoma. Typically, the mutant herpes simplex virus has been modified within the BamHI restriction fragment of the long terminal repeat of the viral genome.

US Patent:

20110262466, Oct 27, 2011

Filed:

Oct 16, 2009

Appl. No.:

13/124295

Inventors:

Vladimir R. Muzykantov - Warwick PA, US
Douglas B. Cines - Wynnewood PA, US
Claudia Gottstein - Carpinteria CA, US
Steven M. Albelda - Philadelphia PA, US

Assignee:

The Trustees of the University of Pennsylvania - Philadelphia PA

International Classification:

A61K 39/395
A61P 7/02
A61P 7/10
A61P 29/00
A61P 9/10
C07K 19/00
A61P 11/00

US Classification:

4241781, 5303917

Abstract:

Compositions are provided comprising a thrombomodulin domain linked to a targeting moiety that binds to a determinant on the surface of a target endothelial cell or red blood cell, wherein the thrombomodulin domain may be the extracellular domain, the N-terminal lectin-like domain, or an epidermal growth factor (EGF)-like domain. The targeting moiety may be a single chain antigen-binding domain (scFv), and the targeting moiety and thrombomodulin domain of the composition may be linked as a continuous polypeptide chain. Methods of delivery and use of a composition described herein are provided, as well as methods of treating or preventing thrombosis, inflammation, tissue ischemia, sepsis, acute lung injury (ALI), acute myocardial infarction (AMI), ischemic stroke, cerebrovascular disease, pulmonary embolism, or ischemic peripheral vascular disease is provided.

US Patent:

20130323283, Dec 5, 2013

Filed:

Dec 1, 2011

Appl. No.:

13/991271

Inventors:

Wayne W. Hancock - Philadelphia PA, US
Steven M. Albelda - Philadelphia PA, US
Philip A. Cole - Baltimore MD, US

Assignee:

THE CHILDREN'S HOSPITAL OF PHILADELPHIA - Philadelphia PA
THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE - Baltimore MD
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA - Philadelphia PA

International Classification:

A61K 31/4155
A61K 38/16
A61K 31/7076
A61K 39/00

US Classification:

4242771, 514404, 424 943, 514 193, 514 47, 514 194, 514 195, 5483657, 530326, 536 2623, 435 32

Abstract:

Methods for treating or preventing a Foxp3+ T regulatory cell (Treg) related disease in a subject in need thereof comprise administering to the subject an effective amount of a pharmaceutical composition comprising an inhibitor of a histone/protein acetyltransferase (HAT). Methods for identifying an agent useful for treating or preventing a Foxp3+ T regulatory cell (Treg) related disease comprise (a) contacting a candidate agent with a test sample comprising Foxp3+ T regulatory cells (Tregs), and (b) comparing a function of the Foxp3+ Tregs in the test sample with that in a control sample, wherein inhibition of the function of the Foxp3+ Tregs in the test sample when compared with the control sample indicates that the candidate agent is an agent useful for treating or preventing a Foxp3+ Treg related disease.